Skip to main content
Content Starts Here GSA Federal Advisory Committee Act (FACA) Database Skip to main content

Committee Detail

Hide Section - GENERAL INFORMATION

GENERAL INFORMATION

Committee NameNational Cancer Institute Board of Scientific AdvisorsAgency NameDepartment of Health and Human Services
Fiscal Year2019Committee Number1483
Original Establishment Date11/20/1985Committee StatusChartered
Actual Termination Date Committee URLhttp://deainfo.nci.nih.gov/advisory/bsa/bsa.htm
New Committee This FYNoPresidential Appointments*No
Terminated This FYNoMax Number of Members*35
Current Charter Date10/8/2017Designated Fed Officer Position Title*DIRECTOR, DIVISION OF EXTRAMURAL ACTIVITIES, NCI
Date Of Renewal Charter10/8/2019Designated Federal Officer Prefix
Projected Termination Date Designated Federal Officer First Name*PAULETTE
Exempt From Renewal*NoDesignated Federal Officer Middle NameS.
Specific Termination AuthorityDesignated Federal Officer Last Name*GRAY
Establishment Authority*Authorized by LawDesignated Federal Officer SuffixPH.D.
Specific Establishment Authority*42 U.S.C. 285a-2(b)(7)Designated Federal Officer Phone*240-276-6340
Effective Date Of Authority*11/20/1985Designated Federal Officer Fax*240-276-7815
Committee Type*ContinuingDesignated Federal Officer Email*grayp@mail.nih.gov
Presidential*No
Committee Function*Scientific Technical Program Advisory Board
Hide Section - RECOMMENDATION/JUSTIFICATIONS

RECOMMENDATION/JUSTIFICATIONS

Agency Recommendation*Continue
Legislation to Terminate RequiredNot Applicable
Legislation StatusNot Applicable
How does cmte accomplish its purpose?*The Board is composed of members who are distinguished scientists from outside the NCI and representatives from the advocacy community. The Board provides scientific advice on a wide variety of matters concerning scientific program policy, progress and future direction of the extramural research programs, and concept review of extramural program initiatives. This includes the evaluation of NCI awarded grants, oversight of concept review of cooperative agreements and contracts initiatives and those activities which it considers meritorious and consistent with the Institute’s programs. The advisory role of the Board is scientific and does not include deliberation on matters of public policy. In 2018, the BSA was presented reports on various topics related to cancer research in general as well as legislative matters. BSA members provided insights regarding a report from the BSA Ad Hoc Subcommittee on Human Immunodeficiency Virus (HIV) and Acquired Immune Deficiency Syndrome (AIDS) Malignancy. As a result, they approved the formation of a BSA Ad Hoc Working Group on Immunology of Therapies and Vaccines and Research Structure to provide further discussion and prioritization of the immunological aspects of developing therapeutic and preventative therapies and vaccines for virus-induced malignancies; understanding the interactions between the immune system and oncogenesis in tumor development; and understanding transmission of oncogenic viruses that cause HIV malignancies, especially KSHV and ways that the research infrastructure for AIDS-associated malignancies could be enhanced. The Board reviewed and deliberated on request for application (RFA) concepts covering a wide variety of topics including the following: Investigation of the Transmission of Kaposi Sarcoma-Associated Herpesvirus (KSHV) (New RFA); Small Business Innovation Research (SBIR) Phase IIB Bridge Awards to Accelerate the Development of Cancer-Focused Technologies Toward Commercialization (Re-issue RFA); NCI Community Oncology Research Program (NCORP) (Re-issue RFA); AIDS and Cancer Specimen Resource (ACSR) (Re-issue RFA/Cooperative Agreement [Coop. Agr.] – Limited Competition); Improving the Reach and Quality of Cancer Care in Rural Populations (New RFA); Tobacco Cessation Interventions Among People Living with HIV/AIDS (New RFA/Coop. Agr.); Cancer Preventive Agent Development Program: Early Phase Clinical Research (New RFA/Coop. Agr.); Cooperative Human Tissue Network (CHTN) (Re-issue RFA/Coop. Agr.); Pathway to Independence Awards for Outstanding Early-Stage Postdoctoral Fellows (K88/R00) (New RFA); NCI Awardee Skills Development Consortium (NASDC) (New RFA/Coop. Agr.); U.S.-China Program for Biomedical Collaborative Research (Re-issue RFA); Early Clinical Trials of New Anticancer Agents with Phase 1 and 2 Emphasis (Re-Issue RFA/Coop. Agr.); Immuno-Oncology Translation Network (IOTN) (New RFA/Coop. Agr.); Implementation Science Center for Cancer Control (IS-C3) (New RFA); Communications and Decision Making in the Context of Risk and Uncertainty for Individuals with Inherited Cancer Syndromes (New RFA); Research to Develop Evidence-Based Approaches to Patient Engagement (New RFA/Coop. Agr.); and Patient Engagement for Priority Cancer Sequencing (PE4PC-Seq) (New RFA/Coop. Agr.).
How is membership balanced?*The Board consists of up to 35 members, including the Chair, appointed by the Director, NCI, from authorities knowledgeable in the fields of laboratory, clinical and biometric research, clinical cancer treatment, cancer etiology, and cancer prevention and control, with emphasis on training and experience in the various disciplines and fields related to scientific areas relevant to carcinogenesis, cancer biology and diagnosis, cancer center administration, medicine, radiological and surgical oncology, cancer chemotherapy, cancer epidemiology, cancer prevention and control, cancer education, cancer information services, community outreach, biological, chemical and physical carcinogenesis, DNA repair and effects, tumor biology and immunology, humoral and cellular immunity, hematopoiesis, cell differentiation and transformation, oncogenes and growth factors, molecular and structural biology and genetic regulation, viral oncology, vaccine development, transplantation, chemotherapy, clinical trial design, management and evaluation, pharmacology, drug development and developmental therapeutics, genetic and immunotherapies, pathology, diagnostic research and cytogenetics, biological response modifiers, imaging, nutrition, survey research, epidemiology, biostatistics, rehabilitation, psychology and behavioral medicine, public health and community oncology, quality of life, pain management, cancer detection and diagnosis, cancer treatment and restorative care, dentistry, nursing, public health, nutrition, education of health professionals, medical oncology, surgery, radiotherapy, gynecologic oncology, pediatric oncology, pathology, and biostatistics. Geographical, gender, ethnic and racial considerations are addressed in selecting members for appointment to the Board.
How frequent & relevant are cmte mtgs?*Meetings are held not less than three times a year. The committee met three times during this reporting period. The Board met jointly with the National Cancer Advisory Board for the November 2017 and June 2018 meetings. The Board also met in March 2018. The Board’s deliberations are an indispensable part of the review of a very large part of the Institute’s extramural program, as well as concept review of grant and contract initiatives in the extramural research program. According to the Board’s charter, approximately three formal meetings are held each year for the review of the extramural programs and concept review of Request for Applications (RFAs); cooperative agreements; and research and development contracts. The BSA Ad hoc Working Group on Immunology of Therapies and Vaccines and Research Structure met on June 13, 2018.
Why advice can't be obtained elsewhere?*This Board is composed of recognized biomedical research authorities from outside the NIH in order to secure unbiased and objective evaluations of extramural research programs. Their recommendations are invaluable because the complex nature of the research requires a unique balance and breadth of expertise not available at NIH or from other established sources.
Why close or partially close meetings?N/A
Recommendation RemarksReports: This committee did not produce any public reports.

Members: Joseph DeSimone left the committee on 4/30/18. The terms for Kenneth Anderson, Dafna Bar-Sagi, Ethan Basch, Arul Chinnaiyan, Chi Dang, Karen Emmons, Maria Martinez, Luis Parada, Mary Smith, and Cheryl Walker have changed due to administrative extensions. As such, their term of service end dates are different than what was reported on the FY17 ACR.

Costs: The operating costs for FY 18 are lower due to the March BSA meeting being held virtually versus in person.

The DFO and Committee Decision Maker positions are held by the same individual because of the assignment of responsibilities within the Institute.
Hide Section - PERFORMANCE MEASURES

PERFORMANCE MEASURES

Outcome Improvement To Health Or Safety*YesAction Reorganize Priorities*Yes
Outcome Trust In GovernmentNoAction Reallocate ResourcesYes
Outcome Major Policy ChangesNoAction Issued New RegulationsNo
Outcome Advance In Scientific ResearchYesAction Proposed LegislationNo
Outcome Effective Grant MakingNoAction Approved Grants Or Other PaymentsNo
Outcome Improved Service DeliveryNoAction OtherNo
Outcome Increased Customer SatisfactionNoAction CommentPriorities are reorganized based on motions made by Board members regarding RFA and RFP concepts. Resources are allocated based on approved concepts.
Outcome Implement Laws/Reg RequirementsNoGrants Review*No
Outcome OtherYesNumber Of Grants Reviewed0
Outcome CommentBased on the approval of the various RFA and RFP concepts, significant advances in cancer research could lead to new treatments, prevention and control initiatives, and behavioral modifications and cures for different cancer sites. Another outcome is the annual posting of the RFA Report.Number Of Grants Recommended0
Cost Savings*Unable to DetermineDollar Value Of Grants Recommended$0.00
Cost Savings CommentMeetings are held not less than three times a year. The committee met three times during this reporting period. The Board met jointly with the National Cancer Advisory Board for the November 2017 and June 2018 meetings. The Board also met in March 2018. Additionally, RFA and RFP concepts are reviewed annually to determine the need for reissuance based on the Board recommendations. Ad hoc Subcommittee and/or working group meetings are held to gather information. Recommendations are reported back at a full board meeting where advice is given to the Institute. The BSA supports the Institute in meeting its mission and as a result even though it can’t be calculated, there are substantive savings.Grants Review CommentNA
Number Of Recommendations*279Access Contact Designated Fed. Officer*Yes
Number Of Recommendations Comment1. A motion to concur on the Office of the Director’s (OD’s) request for applications (RFA) titled “Investigation of the Transmission of Kaposi Sarcoma-Associated Herpesvirus (KSHV)” was approved unanimously. 2. A motion to concur on the OD’s re-issue RFA titled “Small Business Innovation Research (SBIR) Phase II B Bridge Awards to Accelerate the Development of Cancer-Focused Technologies Toward Commercialization” was approved unanimously. 3. A motion to concur on the Division of Cancer Prevention’s re-issue RFA titled “NCI Community Oncology Research Program” was approved unanimously. 4. A motion to concur on the OD’s re-issue RFA/Cooperative Agreement (Coop. Agr.) (Limited Competition) titled “AIDS and Cancer Specimen Resource (ACSR)” was approved unanimously. 5. A motion to establish a BSA Ad Hoc Working Group on Immunology of Therapies and Vaccines and Research Structure was approved unanimously. 6. A motion to concur on the Division of Cancer Control and Population Sciences’ (DCCPS’s) RFA entitled “Improving the Reach and Quality of Cancer Care in Rural Populations” was approved unanimously. 7. A motion to concur on DCCPS’s RFA/Cooperative Agreement (Coop. Agr.) entitled “Tobacco Cessation Interventions Among People Living with HIV/AIDS” was approved unanimously. 8.A motion to concur on the Division of Cancer Prevention’s RFA/Coop. Agr. entitled “Cancer Preventive Agent Development Program: Early Phase Clinical Research” was approved with 23 ayes, zero nays, and 1 abstention. 9. A motion to concur on the re-issuance of the Division of Cancer Treatment and Diagnosis’s RFA/Coop. Agr. entitled “Cooperative Human Tissue Network (CHTN)” was approved with 22 ayes, zero nays, and 2 deferrals, with the consideration to broaden the CHTN geographically to increase racial and ethnic representation in the samples that reflect the diversity of the U.S. population. 10. A motion to accept the report of the 21 June 2017 BSA Ad Hoc HIV and AIDS Malignancy Subcommittee meeting was approved unanimously. 11. A motion to accept the minutes of the March 20, 2018 BSA meeting was approved unanimously. 12. A motion to concur on the Office of the Director’s (OD’s) RFA entitled “Pathway to Independence Awards for Outstanding Early-Stage Postdoctoral Fellows (K88/00)” was approved with 12 ayes, 7 nays, and 0 abstentions, with the stipulation that applications not be discipline-specific. 13. A motion to concur on the OD’s RFA/Cooperative Agreement (Coop. Agr.) entitled “NCI Awardee Skills Development Consortium (NASDC)” was approved unanimously. 14. A motion to concur on the OD’s re-issue RFA entitled “U.S.-China Program for Biomedical Collaborative Research” was approved unanimously. 15. A motion to concur on the Division of Cancer Treatment and Diagnosis’ re-issue RFA/Coop. Agr. entitled “Early Clinical Trials of New Anticancer Agents with Phase 1 and 2 Emphasis” was approved unanimously. 16. A motion to concur on the Division of Cancer Biology’s RFA/Coop. Agr. entitled “Immuno-Oncology Translation Network (IOTN)” was approved unanimously. 17. A motion to concur on the Division of Cancer Control and Population Science’s (DCCPS’s) RFA entitled “Implementation Science Center for Cancer Control (IS-C3)” was approved unanimously. 18. A motion to concur on the DCCPS’s RFA entitled “Communications and Decision Making in the Context of Risk and Uncertainty for Individuals with Inherited Cancer Syndromes” was approved unanimously. 19. A motion to defer on the DCCPS’s RFA/Coop. Agr. entitled “Research to Develop Evidence-Based Approaches to Patient Engagement” was approved unanimously. 20. A motion to defer on the DCCPS’s RFA/Coop. Agr. entitled “Patient Engagement for Priority Cancer Sequencing (PE4PC-Seq)” was approved unanimously.Access Agency WebsiteYes
% of Recs Fully Implemented*90.00%Access Committee WebsiteYes
% of Recs Fully Implemented CommentThe percentage of recommendations implemented as stated above was developed at the time the Annual Comprehensive Review report was prepared. Additional information is available through the RePORT (Research Portfolio Online Reporting Tool) website. RePORT provides access to reports, data, and analyses of NIH research activities that advance the mission of the NIH, including information on NIH expenditures, strategic plans, reports on NIH funding, and reports on the organization and people involved in NIH research and research training. The RePORT website is located at http://report.nih.govAccess GSA FACA WebsiteYes
% of Recs Partially Implemented*10.00%Access PublicationsYes
% of Recs Partially Implemented CommentThe percentage of recommendations implemented stated above was developed at the time the Annual Comprehensive Review report was prepared. Additional information is available through the RePORT (Research Portfolio Online Reporting Tool) website. RePORT provides access to reports, data, and analyses of NIH research activities that advance the mission of the NIH, including information on NIH expenditures, strategic plans, reports on NIH funding, and reports on the organization and people involved in NIH research and research training. The RePORT website is located at http://report.nih.gov.Access OtherYes
Agency Feedback*YesAccess CommentInformation on the BSA can be found at the NCI Division of Extramural Activities: Advisory Boards, Committees and Review Groups website at http://deainfo.nci.nih.gov/advisory/bsa/bsa.htm. Each NCI committee’s charter, minutes, agenda, roster, future meeting dates, meeting PowerPoint presentations and reports is located here. Additionally, the public may view the BSA meetings (both live and on demand) via the NIH Videocast at the following website: http://videocast.nih.gov/.
Agency Feedback CommentThe NCI Director’s Report is presented at each Board meeting. Each NCI Division gives an update regarding progress of approved RFAs, cooperative agreements and contract concepts. Also, the Annual RFA Report is presented at each November/December Joint BSA/National Cancer Advisory Board meeting to show RFAs published and reviewed. A list of action items are assigned to individual NCI staff with specific time frames with deadlines.Narrative Description*The goal of NIH research is to acquire new knowledge to help prevent, detect, diagnose, and treat disease and disability, from the rarest genetic disorder to the common cold. The NIH mission is to uncover new knowledge that will lead to better health for everyone. NIH works toward that mission by the National Cancer Institute Board of Scientific Advisor’s (BSA). The BSA is composed of distinguished scientists from outside the NCI and representatives from the advocacy community. The BSA provides scientific advice on a wide variety of matters concerning scientific program policy, reviews the progress and future direction of the extramural research programs, and concept review of extramural program initiatives. This includes the oversight of research and development, concept review of request for applications, cooperative agreements, initiatives and other programmatic activities. The advisory role of the BSA is scientific and does not include deliberation on matters of public policy. The BSA represents the scientific community's voice in the extramural science the NCI supports. As such, the Board advises the NCI leadership on the progress and future direction of the Institute's Extramural Research Program. The Board evaluates NCI extramural programs, and reviews ideas for new research opportunities and solicitations to ensure that a concept is meritorious and consistent with the Institute's mission. Additionally, the BSA believes it is important to interact with and receive feedback from the clinical, population science, and laboratory research communities affected by NCI policies. The BSA’s deliberations are an indispensable part of the review of a very large part of the Institute's extramural program.
Hide Section - COSTS

COSTS

Payments to Non-Federal Members* Est Payments to Non-Fed Members Next FY* 
Payments to Federal Members* Est. Payments to Fed Members Next FY* 
Payments to Federal Staff* Estimated Payments to Federal Staff* 
Payments to Consultants* Est. Payments to Consultants Next FY* 
Travel Reimb. For Non-Federal Members* Est Travel Reimb Non-Fed Members nextFY* 
Travel Reimb. For Federal Members* Est Travel Reimb For Fed Members* 
Travel Reimb. For Federal Staff* Est. Travel Reimb to Fed Staff Next FY* 
Travel Reimb. For Consultants* Est Travel Reimb to Consultants Next FY* 
Other Costs Est. Other Costs Next FY* 
Total Costs$0.00Est. Total Next FY*$0.00
Federal Staff Support (FTE)* Est. Fed Staff Support Next FY* 
Hide Section - Custom Links

Custom Links

     Committee Level Reports               
Hide Section - MEMBERS,MEETINGS AND ADVISORY REPORTS

MEMBERS,MEETINGS AND ADVISORY REPORTS

To View all the members, meetings and advisory reports for this committee please click here
Hide Section - CHARTERS AND RELATED DOCS

CHARTERS AND RELATED DOCS

No Documents Found
Hide Section - DATA FROM PREVIOUS YEARS

DATA FROM PREVIOUS YEARS

Committee

Data from Previous Years

 
ActionCommittee System IDCommittee NameFiscal Year
 COM-001923National Cancer Institute Board of Scientific Advisors2017
 COM-002258National Cancer Institute Board of Scientific Advisors2016
 COM-004079National Cancer Institute Board of Scientific Advisors2015
 COM-004408National Cancer Institute Board of Scientific Advisors2014
 COM-006156National Cancer Institute Board of Scientific Advisors2013
 COM-006867National Cancer Institute Board of Scientific Advisors2012
 COM-008324National Cancer Institute Board of Scientific Advisors2011
 COM-009069National Cancer Institute Board of Scientific Advisors2010
 COM-010116National Cancer Institute Board of Scientific Advisors2009
 COM-011002National Cancer Institute Board of Scientific Advisors2008
 COM-012119National Cancer Institute Board of Scientific Advisors2007
 COM-012487National Cancer Institute Board of Scientific Advisors2006
 COM-013962National Cancer Institute Board of Scientific Advisors2005
 COM-014543National Cancer Institute Board of Scientific Advisors2004
 COM-016033National Cancer Institute Board of Scientific Advisors2003
 COM-016593National Cancer Institute Board of Scientific Advisors2002
 COM-017634National Cancer Institute Board of Scientific Advisors2001
 COM-018354National Cancer Institute Board of Scientific Advisors2000
 COM-019571National Cancer Institute Board of Scientific Advisors1999
 COM-020365National Cancer Institute Board of Scientific Advisors1998
 COM-021711National Cancer Institute Board of Scientific Advisors1997
 COM-034777National Cancer Institute Board of Scientific Advisors2018